Swiss drug major Novartis AG (NVS) tightened its fiscal 2020 sales guidance on Tuesday, as second-quarter profit and sales declined, largely due to higher impairments. Meanwhile, Q2 core earnings rose and surpassed Wall Street analysts' estimate.
from RTT - Earnings https://ift.tt/2OKfZ5a
via IFTTT
No comments:
Post a Comment